Abstract
TRK fusions are oncogenic drivers of various adult and paediatric cancers. The first-generation TRK inhibitors, larotrectinib and entrectinib, were gr......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
